Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
8.81
-0.28 (-3.08%)
Apr 8, 2026, 1:11 PM EDT - Market open
Immix Biopharma Employees
As of December 31, 2024, Immix Biopharma had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-$1,401,839
Market Cap
467.04M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2023 | 17 | 6 | 54.55% | 14 | 3 |
| Dec 31, 2022 | 11 | 9 | 450.00% | 9 | 2 |
| Dec 31, 2021 | 2 | - | - | 2 | 0 |
| Sep 30, 2021 | 2 | - | - | 2 | 0 |
| Jun 30, 2021 | 2 | - | - | 2 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| ADC Therapeutics | 193 |
| Absci | 140 |
| Aura Biosciences | 113 |
| Verastem | 102 |
| enGene Holdings | 82 |
| Assembly Biosciences | 73 |
| Lexeo Therapeutics | 59 |
IMMX News
- 9 days ago - Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones - GlobeNewsWire
- 5 weeks ago - Immix Biopharma to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 - GlobeNewsWire
- 4 months ago - Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 months ago - Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 months ago - At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - GlobeNewsWire
- 5 months ago - Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch - GlobeNewsWire
- 5 months ago - Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 - GlobeNewsWire